Business
BioMarin Announces Third Quarter 2021 Financial Results and Corporate Updates
- Strong Commercial Launch of VOXZOGO™ for the Treatment of Children with Achondroplasia Ages 2 and Older Underway across Europe; U.S. Review Proceeding,
About this update from Biomarin Pharmaceutical Inc.
[{"type":"text","content":"- Strong Commercial Launch of VOXZOGO™ for the Treatment of Children with Achondroplasia Ages 2 and Older Underway across Europe; U.S. Review Proceeding, Target Action Date Tracking to November 20, 2021\n - European Opinion on the Marketing Authorization Application (MAA) for Valoctocogene Roxaparvovec, for the Treatment of Severe Hemophilia A, Expected First Half 2022; U.S. Resubmission of Biologics License Application (BLA) in U.S. on Track for Second Quarter 2022\n - Improving Full-year 2021 Total Revenue and Bottom-line Financial Guidance\n - Multiple Early-stage Programs to be Shared at Upcoming BioMarin R&D Day on November 30, 2021\n\n\nSAN RAFAEL, Calif., Oct. 27, 2021 /PRNewswire/ -- \n\n \n \n \n \n \n \n\n \nFinancial Highlights (in millions of U.S. dollars, except per share data, unaudited)\nThree Months Ended September 30,\nNine Months Ended September 30,\n2021\n2020\n% Change\n2021\n2020\n% Change\nTotal Revenues\n$\n408.7\n$\n476.8\n(14)\n%\n$\n1,396.5\n$\n1,408.3\n(1)\n%\nNet Product Revenues Marketed by BioMarin (1)\n$\n369.5\n$\n419.8\n(12)\n%\n$\n1,245.8\n$\n1,239.9\n—\n%\nVimizim Net Product Revenues\n$\n136.9\n$\n147.9\n(7)\n%\n$\n466.8\n$\n401.8\n16\n%\nNaglazyme Net Product Revenues\n$\n71.2\n$\n76.3\n(7)\n%\n$\n297.3\n$\n271.6\n9\n%\nKuvan Net Product Revenues\n$\n67.7\n$\n124.1\n(45)\n%\n$\n217.3\n$\n368.7\n(41)\n%\nPalynziq Net Product Revenues\n$\n60.7\n$\n46.1\n32\n%\n$\n173.7\n$\n121.4\n43\n%\nBrineura Net Product Revenues\n$\n32.9\n$\n25.4\n30\n%\n$\n90.6\n$\n75.2\n20\n%\nVoxzogo Net Product Revenues\n$\n0.1\n$\n—\nn/a\n$\n0.1\n$\n—\nn/a\nAldurazyme Net Product Revenues\n$\n24.4\n$\n40.9\n(40)\n%\n$\n102.5\n$\n128.9\n(20)\n%\nGAAP Net Income (Loss)\n$\n(36.5)\n$\n784.8\n$\n(6.2)\n$\n837.0\nGAAP Net Income (Loss) per Share – Basic\n$\n(0.20)\n$\n4.33\n$\n(0.03)\n$\n4.63\nGAAP Net Income (Loss) per Share – Diluted\n$\n(0.20)\n$\n4.01\n$\n(0.03)\n$\n4.39\nNon-GAAP Income (2)\n$\n33.5\n$\n98.7\n$\n235.7\n$\n272.6\nSeptember 30,2021\nDecember 31,2020\nCash, cash equivalents and investments\n$\n1,546.1\n$\n1,350.9\n(1)\nNet Product Revenues Marketed by BioMarin is the sum of revenues from Vimizim, Naglazyme, Kuvan, Palynziq, Brineura and Voxzogo (formerly known as vosoritide) for the three and nine months ended September 30, 2021 and includes Firdapse for the nine months ended September 30, 2020, each calc...